The Undeniable Fact of a Pro-Big-Business Supreme Court

Three years ago, Professor Richard Epstein of the University of Chicago was peddling falsehoods and misconceptions about malpractice law that wouldn’t pass a 1L Torts class. Via Walter Olson, I see he’s back with a piece titled, “The Myth of a Pro-Business SCOTUS,” claiming “Commentators inaccurately condemn the five conservative justices as corporate shills.”

Mutual Pharmaceutical Co., Inc. V. Bartlett—Catch-22 for the Generic Pharmaceutical Agency

By | IP Law Alert | July 10, 2013
Mutual Pharmaceutical Co., Inc. V. Bartlett—Catch-22 for the Generic Pharmaceutical Agency

The generic pharmaceutical industry faced a Catch-22 when a serious adverse reaction arose from use of a generic drug product, and the manufacturer was restrained from unilaterally amending the product label to conform to state requirements, due to the Supreme Court’s decision in PLIVA, Inc. v. Mensing, 131 S.Ct. 2567 (2011).

Supreme Court Closes Courthouse Doors to Patients Harmed by Generic Drugs

Supreme Court Closes Courthouse Doors to Patients Harmed by Generic Drugs

Karen Bartlett took a generic drug called sulindac that her doctor prescribed to her for shoulder pain.  About three weeks later,  her skin began to peel off due to a reaction to the drug.  She is now left with burn-like lesions over two-thirds of her body and she is nearly blind.   She spent months in a burn unit in a medically induced coma.